2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2084

Why so Fast? A Focus on Reasons for an Increase in Arthritis-Attributable Activity Limitation Trends, 2002-2017
Abstract Number: 2085

Too Soon to Say: Promising Results from a Community-Delivered RCT Examining Work-Related Outcomes of the Chronic Disease Self-Management Program
Abstract Number: 2086

Arthritis-Attributable Work Limitation Variation by U.S. County Classifications and Selected Characteristics, 2017
Abstract Number: 2087

Prevalence of Corticosteroid Use in Incidental Vertebral or Hip Fractures
Abstract Number: 2088

When It Just Won’t Stop: Chronic Pain and High Impact Chronic Pain Among U.S. Adults with Arthritis
Abstract Number: 2089

Restricting Activity to Evade Knee Symptoms Is Associated with Worse Physical Function and Radiographic Osteoarthritis
Abstract Number: 2090

Differences in Stepping and Standing Based on Self-reported Exercise Identity in Persons Following Total Knee Replacement
Abstract Number: 2091

The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients
Abstract Number: 2092

Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials
Abstract Number: 2093

Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases
Abstract Number: 2094

Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination
Abstract Number: 2095

A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients
Abstract Number: 2096

An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients
Abstract Number: 2097

Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis
Abstract Number: 2098

Distinctive Pattern of LTBI Screening Parameters in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) in Endemic Areas

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].